Navigation Links
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data

OTTAWA, April 11 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called "good cholesterol," today announced information from further analysis of the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and heart disease.

A detailed review of patient information indicated that all blood chemistry and blood pressure measurements were within the normal or expected ranges. CRD5 was shown to be safe in dyslipidemic patients. In addition, the drug was well-tolerated in the patient group, with the exception of the reported GI adverse events that led to the cessation of the 5 gram dosing phase.

As previously reported, the overall mean HDL increase was 5% at both the 1g (n=50) and 3g (n=40) dosing levels but the patient to patient variation was high. While some patients had a negative response, over 20% of patients achieved more than a 10% rise in HDL at the lower dose levels.

The patient information was reviewed to determine if there were any patient characteristics that had an impact on the efficacy of CRD5. Some patients were taking other medications during the trial that may have had lipid altering effects and these subjects appeared to have reduced response to CRD5. Data from these subjects were removed and the trial results were reanalyzed. CRD5 appeared to be more effective in patients with baseline plasma HDL-cholesterol levels of less than 0.9 mM. This level of HDL is considered to be abnormal and is associated with elevated risk of developing heart disease. Those patients (n=17) with starting HDL levels below 0.9 mM averaged an 11% increase in HDL levels from baseline at the 3 gram CRD5 dosing level.

Of note, several patients were identified to have taken proton pump inhibitors (PPI), such as ranitidine and lansoprazole,
'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Further Analysis CRD5 Phase Clinical Trial Data
(Date:1/23/2015)... Inc., a leader in hand hygiene monitoring, today announced ... subsidiary of Ascendis Health Limited, in Johannesburg, ... of millions of patients around the world are affected ... patient to patient via the unwashed hands of healthcare ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... April 24 Choice Hotels,International (Choice) announced today ... insurance plan from Planned Administrators Inc.,(PAI), available to ... With the announcement, the franchisees that own ... in the United States now have the option ...
... 24 Boston Scientific,Corporation (NYSE: BSX ... the,Multicenter Automatic Defibrillator Implantation Trial with Cardiac,Resynchronization ... examines the potential benefits of Boston Scientific ... population of,heart failure patients. It is the ...
... Research Confirms Rounder Teeth Provide More Feminine and Youthful ... ... dentist Denise,Fundora, DDS ( http://www.fundoradental.com ) of Beverly Hills, CA states,"Changing the ... as rejuvenate your overall appearance. Some of my patients,say that a smile ...
... Their Computerized,Prescribing Systems Are Effective, First Use ... Survey, WASHINGTON, April 24 With the ... becomes the,first health care quality organization to add ... computerized medication prescribing systems are actually,catching common, serious ...
... of cancer, study warns , , THURSDAY, April 24 (HealthDay ... been successfully treated if ovarian or testicular tissue they ... back into their bodies without it being adequately checked ... , Researchers at two university hospitals in Israel, writing ...
... 24 Life Brokerage Partners,announces three additional carrier ... Polaris and United National Finance,Inc. ("UNF"). These premium ... they provide new methods for transacting,business., The ... and UNF,do not end with the agents, but ...
Cached Medicine News:Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 2Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 3Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 2Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 3Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 3Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 4Health News:Stored Ovarian Tissue Needs Testing Before Re-Implantation 2Health News:Life Brokerage Partners Strengthens Premium Finance Programs 2
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Latex-free coronary artery perfusion/cardioplegia infusion cannulae....
... OXYPLETH is seven pounds of ... technology combined with software developed over ... team provides the ultimate in non-invasive ... unique oximeter monitor technology and sophisticated ...
... The ODISsey Tissue Oximeter is a lightweight, ... LCD display monitor with two separate channels for ... and cables as well as adjustable alarms for ... The system is very user friendly and requires ...
Medicine Products: